Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 373 to 375 of 375 entries
Sorted by: Best Match Show Resources per page
Hypoxic-Ischemic Encephalopathy-Induced Seizure in an 11-Year-Old Female.

Cureus

Pandav K, Ishak A, Chohan F, Edaki O, Quinonez J, Ruxmohan S.
PMID: 34447644
Cureus. 2021 Jul 24;13(7):e16606. doi: 10.7759/cureus.16606. eCollection 2021 Jul.

Hypoxic-ischemic encephalopathy (HIE) typically manifests in the neonatal period. The degree of hypoxia following intrapartum asphyxia determines the structural changes in the brain, which can cause functional deficits in the affected child leading to developmental deficits and recurrent seizures....

Cite
Pandav K, Ishak A, Chohan F, et al. Hypoxic-Ischemic Encephalopathy-Induced Seizure in an 11-Year-Old Female. Cureus. 2021;13(7):e16606doi: 10.7759/cureus.16606.
Pandav, K., Ishak, A., Chohan, F., Edaki, O., Quinonez, J., & Ruxmohan, S. (2021). Hypoxic-Ischemic Encephalopathy-Induced Seizure in an 11-Year-Old Female. Cureus, 13(7), e16606. https://doi.org/10.7759/cureus.16606
Pandav, Krunal, et al. "Hypoxic-Ischemic Encephalopathy-Induced Seizure in an 11-Year-Old Female." Cureus vol. 13,7 (2021): e16606. doi: https://doi.org/10.7759/cureus.16606
Pandav K, Ishak A, Chohan F, Edaki O, Quinonez J, Ruxmohan S. Hypoxic-Ischemic Encephalopathy-Induced Seizure in an 11-Year-Old Female. Cureus. 2021 Jul 24;13(7):e16606. doi: 10.7759/cureus.16606. eCollection 2021 Jul. PMID: 34447644; PMCID: PMC8382482.
Copy Download .nbib Format: NLM
Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial.

Cancer

Romesser PB, Sherman EJ, Whiting K, Ho ML, Shaha AR, Sabra MM, Riaz N, Waldenberg TE, Sabol CR, Ganly I, McBride SM, Fagin JA, Zhang Z, Tuttle RM, Wong RJ, Lee NY.
PMID: 34293201
Cancer. 2021 Nov 15;127(22):4161-4170. doi: 10.1002/cncr.33804. Epub 2021 Jul 22.

BACKGROUND: The use of external-beam radiotherapy for locally advanced nonanaplastic thyroid cancer remains controversial. This prospective study evaluated the efficacy and tolerability of intensity-modulated radiation therapy (IMRT) with or without concurrent chemotherapy in patients with locally advanced thyroid cancer.METHODS:...

Cite
Romesser PB, Sherman EJ, Whiting K, et al. Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. Cancer. 2021;127(22):4161-4170doi: 10.1002/cncr.33804.
Romesser, P. B., Sherman, E. J., Whiting, K., Ho, M. L., Shaha, A. R., Sabra, M. M., Riaz, N., Waldenberg, T. E., Sabol, C. R., Ganly, I., McBride, S. M., Fagin, J. A., Zhang, Z., Tuttle, R. M., Wong, R. J., & Lee, N. Y. (2021). Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. Cancer, 127(22), 4161-4170. https://doi.org/10.1002/cncr.33804
Romesser, Paul B, et al. "Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial." Cancer vol. 127,22 (2021): 4161-4170. doi: https://doi.org/10.1002/cncr.33804
Romesser PB, Sherman EJ, Whiting K, Ho ML, Shaha AR, Sabra MM, Riaz N, Waldenberg TE, Sabol CR, Ganly I, McBride SM, Fagin JA, Zhang Z, Tuttle RM, Wong RJ, Lee NY. Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. Cancer. 2021 Nov 15;127(22):4161-4170. doi: 10.1002/cncr.33804. Epub 2021 Jul 22. PMID: 34293201.
Copy Download .nbib Format: NLM
A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Contemporary clinical trials communications

Yamada M, Miller DM, Lowe M, Rowe C, Wood D, Soyer HP, Byrnes-Blake K, Parrish-Novak J, Ishak L, Olson JM, Brandt G, Griffin P, Spelman L, Prow TW.
PMID: 34401600
Contemp Clin Trials Commun. 2021 Aug 04;23:100830. doi: 10.1016/j.conctc.2021.100830. eCollection 2021 Sep.

BLZ-100 (tozuleristide) is an intraoperative fluorescent imaging agent that selectively detects malignant tissue and can be used in real time to guide tumor resection. The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of BLZ-100...

Cite
Yamada M, Miller DM, Lowe M, et al. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemp Clin Trials Commun. 2021;23:100830doi: 10.1016/j.conctc.2021.100830.
Yamada, M., Miller, D. M., Lowe, M., Rowe, C., Wood, D., Soyer, H. P., Byrnes-Blake, K., Parrish-Novak, J., Ishak, L., Olson, J. M., Brandt, G., Griffin, P., Spelman, L., & Prow, T. W. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary clinical trials communications, 23100830. https://doi.org/10.1016/j.conctc.2021.100830
Yamada, Miko, et al. "A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients." Contemporary clinical trials communications vol. 23 (2021): 100830. doi: https://doi.org/10.1016/j.conctc.2021.100830
Yamada M, Miller DM, Lowe M, Rowe C, Wood D, Soyer HP, Byrnes-Blake K, Parrish-Novak J, Ishak L, Olson JM, Brandt G, Griffin P, Spelman L, Prow TW. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemp Clin Trials Commun. 2021 Aug 04;23:100830. doi: 10.1016/j.conctc.2021.100830. eCollection 2021 Sep. PMID: 34401600; PMCID: PMC8355837.
Copy Download .nbib Format: NLM
Showing 373 to 375 of 375 entries